4 Value Stocks to Invest in for the Second-Half 2025 Market Shift

For the second half of 2025, a value investing strategy is recommended, prioritizing companies with low Price to Cash Flow (P/CF) ratios and strong financial health amidst cautious market sentiment. Four specific stocks—Hudbay Minerals (HBM), StoneCo (STNE), Centene (CNC), and CVS Health (CVS)—are identified as compelling opportunities, exhibiting low P/CF, positive sales and EPS growth estimates, and high Value Scores, making them suitable for long-term portfolios.

Analysis

Amid a market repositioning characterized by a 0.91% rise in the Dow Jones Industrial Average and declines in the S&P 500 and Nasdaq, the article posits a strategic shift toward value equities for the second half of 2025. This thesis is supported by a screening methodology that prioritizes the Price-to-Cash-Flow (P/CF) ratio, a metric less susceptible to accounting manipulations than earnings. Four companies have been identified through this screen: Hudbay Minerals (HBM), StoneCo (STNE), Centene (CNC), and CVS Health (CVS). Hudbay Minerals stands out with a projected 41.7% EPS growth and a 50% average earnings surprise. StoneCo shows solid growth with a projected 10.9% increase in sales. Both CVS and Centene, despite Centene's 15.1% share price decline over the past year, exhibit strong value characteristics, with CVS projecting 12.9% EPS growth and Centene showing a 10.1% sales growth forecast and a significant 25.5% average earnings surprise. All four companies possess favorable Zacks Ranks and Value Scores, suggesting they are fundamentally sound but potentially undervalued relative to their cash generation capabilities.

Key Decisions for Investors

• Consider allocating capital to value stocks screened for low Price-to-Cash-Flow ratios, as this may offer a defensive posture in a market showing signs of rotation from growth to value.
• Investors should conduct further due diligence on HBM, STNE, CNC, and CVS, as they exhibit a compelling combination of positive growth forecasts, strong earnings surprise histories, and attractive valuation metrics.
• Centene (CNC) warrants particular attention as a potential contrarian investment, given its 15.1% share price underperformance over the past year contrasts sharply with its positive sales growth outlook and strong Value Score.
• Monitor for continued sector rotation and be prepared for a long-term investment horizon, as the outperformance of value stocks is contingent on a sustained shift in investor sentiment and recognition of their underlying fundamentals.